The Board of Directors and the Chief Executive Officer of ODI Pharma AB ("ODI Pharma") hereby publishes the annual report for the fiscal year 2024/2025. The annual report, along with the accompanying auditor's report, is available as an attached file and on the websites of ODI Pharma (www.odipharma.com) and Spotlight Stock Market (www.spotlightstockmarket.com).
The auditor has made the following observation:
Material uncertainty relating to going concern
Without qualifying our opinion, we draw attention to the Directors' report on page 16 and note 18 of the annual accounts and consolidated accounts which indicate that additional funding is required to continue as a going concern. Failure to obtain new funding could materially affect its ability to continue as a going concern. These circumstances indicate the existence of a material uncertainty that may cast significant doubt about the company's ability to continue as a going concern.
ODI Pharma's comment regarding material uncertainty related to the going concern assumption
"We are seeing a strong start to the new financial year with clear revenue growth during the first five months. It is crucial that this positive trend continues. Our focus is now on strengthening our operational presence in Poland, creating a solid platform for further geographic expansion."
For more information on ODI Pharma, please contact:
Volker Wiederrich, Chairman, ODI Pharma AB
E-mail: info@odipharma.com
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.